The Value of Expression of M2-PK and VEGF in Patients with Advanced Gastric Cancer

被引:29
作者
Yin, Lanning [1 ]
Wang, Xiang [2 ]
Luo, Changjiang [1 ]
Liu, Haipeng [1 ]
Zhang, Ling [1 ]
Zhang, Hong [1 ]
Zhang, Youcheng [1 ]
机构
[1] Lanzhou Univ, Hosp 2, Dept Gen Surg, Lanzhou 730030, Gansu, Peoples R China
[2] Lanzhou Univ, Hosp 2, Dept Gastroenterol, Lanzhou 730030, Gansu, Peoples R China
关键词
M2 pyruvate kinase isoenzyme; Vascular endothelial growth factor; Advanced gastric cancer; ENDOTHELIAL GROWTH-FACTOR; M2; PYRUVATE-KINASE; TUMOR M2-PYRUVATE KINASE; COLORECTAL-CANCER; LUNG-CANCER; TU M2-PK; MARKER; METASTASIS; STATISTICS; PROGNOSIS;
D O I
10.1007/s12013-013-9601-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glycolytic pyruvate kinase isoenzyme type M2 (M2-PK) plays a key role in tumor metabolism and energy production. Vascular endothelial growth factor (VEGF) is critical in regulating angiogenesis which is an essential process required for tumor growth and metastasis. These two genes may function in accordance with tumor development. The purpose of this study was to investigate the relationship between the expression of M2-PK and VEGF, and their association with clinicopathological features in patients with advanced gastric cancer. Expression of M2-PK and VEGF were examined in 142 cases of paraffin-embedded tissue blocks from patients with advanced gastric cancer. M2-PK expression was found to strongly correlate with that of VEGF (r = 0.718). In addition, expression of M2-PK and VEGF correlates with tumor size (p = 0.0001, and p = 0.0017, respectively), depth of invasion (p = 0.0024, and p = 0.0261, respectively), and lymph node metastasis (p = 0.036, and p = 0.028, respectively). The high expression levels of M2-PK and VEGF may indicate poor prognosis in patients with advanced gastric cancer.
引用
收藏
页码:1033 / 1039
页数:7
相关论文
共 36 条
[1]   IMPROVING SURVIVAL IN GASTRIC-CANCER - REVIEW OF 5-YEAR SURVIVAL RATES IN ENGLISH-LANGUAGE PUBLICATIONS FROM 1970 [J].
AKOH, JA ;
MACINTYRE, IMC .
BRITISH JOURNAL OF SURGERY, 1992, 79 (04) :293-299
[2]   GASTRIC-CANCER - A 25-YEAR REVIEW [J].
ALLUM, WH ;
POWELL, DJ ;
MCCONKEY, CC ;
FIELDING, JWL .
BRITISH JOURNAL OF SURGERY, 1989, 76 (06) :535-540
[3]   Gastric cancer [J].
Catalano, Vincenzo ;
Labianca, Roberto ;
Beretta, Giordano D. ;
Gatta, Gemma ;
De Braud, Filippo ;
Van Cutsem, Eric .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 71 (02) :127-164
[4]   Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature [J].
Des Guetz, G. ;
Uzzan, B. ;
Nicolas, P. ;
Cucherat, M. ;
Morere, J-F ;
Benamouzig, R. ;
Breau, J-L ;
Perret, G-Y .
BRITISH JOURNAL OF CANCER, 2006, 94 (12) :1823-1832
[5]   Combination of Low Vascular Endothelial Growth Factor A (VEGF-A)/VEGF Receptor 2 Expression and High Lymphocyte Infiltration Is a Strong and Independent Favorable Prognostic Factor in Patients With Nonsmall Cell Lung Cancer [J].
Donnem, Tom ;
Al-Shibli, Khalid ;
Andersen, Sigve ;
Al-Saad, Samer ;
Busund, Lill-Tove ;
Bremnes, Roy M. .
CANCER, 2010, 116 (18) :4318-4325
[6]  
EIGENBRODT E, 1992, Critical Reviews in Oncogenesis, V3, P91
[7]  
Eigenbrodt E, 1997, ANTICANCER RES, V17, P3153
[8]   Why do cancers have high aerobic glycolysis? [J].
Gatenby, RA ;
Gillies, RJ .
NATURE REVIEWS CANCER, 2004, 4 (11) :891-899
[9]   Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy [J].
Giralt, Jordi ;
Navalpotro, Begona ;
Hermosilla, Eduardo ;
de Torres, Ines ;
Espin, Eloi ;
Reyes, Victoria ;
Cerezo, Laura ;
de las Heras, Manuel ;
Ramon y Cajal, Santiago ;
Armengol, Manel ;
Benavente, Sergi .
ONCOLOGY, 2006, 71 (5-6) :312-319
[10]   Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer - Evidence for a novel biological marker of adverse prognosis [J].
Goonetilleke, Kolitha S. ;
Mason, James M. ;
Siriwardana, Priyantha ;
King, Nicholas K. ;
France, Michael W. ;
Siriwardena, Ajith K. .
PANCREAS, 2007, 34 (03) :318-324